The Good, the Bad, and the Ugly: Hyperprogression in Cancer Patients Following Immune Checkpoint Therapy

Genome Medicine - United Kingdom
doi 10.1186/s13073-019-0661-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC